An Australian stem cell and regenerative medicine company

December 08, 2015

Rodman & Renshaw Equity Research: Powering Production of Stem Cells

View Report

Scalability and sustainability in stem cell manufacturing. We initiate coverage on Cynata Therapeutics Ltd. with a Buy rating and 12-month price target of A$1.00 per share. Cynata is an Australian stem cell-focused firm with a proprietary platform, CymerusTM, which provides a high-throughput, sustainable solution for the production of mesenchymal stem cells (MSCs).

September 03, 2015

SeeThruEquity Research Report

View Report

Cynata Initiation Report

February 19, 2015

Baillieu Holst Equity Research Update - 19 Feb 2015

View Report

Manufacturing validated for Therapeutic Scale-Up consistent, reproducible stem cells in unlimited quantities!

Analyst: Russell Wright

May 30, 2014

Baillieu Holst Equity Research

View Report

Initiation of Coverage: “Unlimited quantities of potent adult stem cells, no hassles”

Analyst: Stuart Roberts